Bicyclic amines as novel JAK kinase inhibitors

A compound according to general formula I

• wherein
• R1 is methyl or ethyl;
• n is 1 or 2;
• R2 is selected from the group consisting of hydrogen, cyano, —SO2Ra, —SO2NRbRc, —C(O)Rb, phenyl, and 5- and 6-membered heteroaryl, wherein said phenyl, 5- and 6-membered heteroaryl are optionally substituted with one or more substituents independently selected from R3,
• R3 is selected from the group consisting of hydroxyl, cyano, halogen, (C1-C4)alkyl, hydroxyl(C1-C4)alkyl, halo(C1-C4)alkyl, cyano(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, —SO2Ra, and —SO2NRbRc;
• Ra is selected from the group consisting of (C1-C4)alkyl, (C3-C6)cycloalkyl, halo(C1-C4)alkyl, and cyano(C1-C4)alkyl;
• Rb and Rc are each independently selected from the group consisting of hydrogen, (C1-C4)alkyl, halo(C1-C4)alkyl, cyano(C1-C4)alkyl, (C3-C6)cycloalkyl, halo(C3-C6)cycloalkyl, and cyano(C3-C6)cycloalkyl;
• or a pharmaceutically acceptable salt, hydrate, or solvate thereof.